21 Jun 2022 Merck Presents Positive Results from Phase 1/2 Study Evaluating V116, the Company’s Investigational Pneumococcal Conjugate Vaccine for Adults
20 Jun 2022 Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
13 Jun 2022 Sanofi-GSK next-generation COVID-19 booster delivers strong immune response against variants of concern, including Omicron
11 Jun 2022 GSK announces positive pivotal phase III data for its respiratory syncytial virus (RSV) vaccine candidate for older adults
06 Jun 2022 GSK announces US FDA approval of Priorix for the prevention of measles, mumps and rubella in individuals 12 months of age and older
06 Jun 2022 Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
06 Jun 2022 Nouscom Announces Positive Full Phase 1 Data of NOUS-209, an 'off-the-shelf' Neoantigen Cancer Immunotherapy for the Treatment of dMMR/MSI-H Solid Tumors, at ASCO 2022
06 Jun 2022 Positive Phase 1 Data from mRNA-based Individualized Neoantigen Specific Immunotherapy in Patients with Resected Pancreatic Cancer presented at ASCO
05 Jun 2022 HOOKIPA announces positive Phase 1 data and Phase 2 plans for HB-200 program for the treatment of advanced head and neck cancers at ASCO
01 Jun 2022 Clover Doses First Participants in Phase 1 Trial with SCB-2020S, a Potentially Broadly Protective Chimeric COVID-19 Vaccine Candidate
30 May 2022 RhoVac's phase IIb study in prostate cancer , BRaVac, failed to meet its primary endpoint
27 May 2022 Nurix Therapeutics Announces Positive Dose Finding Data in Chronic Lymphocytic Leukemia and Advances NX-2127 to Next Phase of Clinical Development
26 May 2022 Daiichi Sankyo Announces Development Progress of mRNA COVID-19 Vaccine (DS-5670) in Japan
23 May 2022 RAPT Therapeutics Announces Initiation of Phase 2b Trial of RPT193 in Patients with Moderate-to-Severe Atopic Dermatitis
23 May 2022 Anokion Announces Positive Data from Phase 1 ACeD Clinical Trial Evaluating KAN-101 as a Treatment for Celiac Disease Presented in a Plenary Session at DDW 2022
23 May 2022 Vaxzevria approved in the EU as third dose booster against COVID-19
19 May 2022 US FDA accepts Cytovation's IND application for Phase II combination studies of CyPep-1, a first-in-class targeted tumor membrane immunotherapy
19 May 2022 EMA accepts filing of marketing authorization application for Valneva’s inactivated COVID-19 Vaccine Candidate
18 May 2022 Pfizer and BioNTech Granted U.S. Emergency Use Authorization for Booster Dose of Their COVID-19 Vaccine in Children 5 Through 11 Years of Age
17 May 2022 Nouscom Announces Janssen Receives US FDA IND Clearance for VAC85135, an 'Off-The-Shelf' Cancer Immunotherapy Developed using Nouscom's Proprietary Viral Vector Platform
13 May 2022 Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster
10 May 2022 Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates
02 May 2022 VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine
02 May 2022 HilleVax Announces Initiation of Phase 2b Clinical Trial of HIL-214 Vaccine Candidate for the Prevention of Norovirus-Related Acute Gastroenteritis in Infants
20 Apr 2022 Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up